Drug intelligence / Profile preview

ef5

Development stage: Phase 2
Lead developer: University of Pennsylvania
Modality: Small Molecules
Administration: Intravenous

Overview

EF5 is a fluorinated derivative of the 2-nitroimidazole etanidazole developed as a hypoxia marker for research and clinical imaging. It selectively binds to hypoxic cells by forming adducts with intracellular macromolecules in the absence of oxygen. This property allows EF5 to be used for detecting and quantifying tissue hypoxia in animal models and human tumors through immunohistochemistry or PET imaging when radiolabeled (e.g., 18F-EF5). The compound was developed at the University of Pennsylvania by Dr. Cameron Koch and Dr. Sydney Evans. EF5 is characterized by its lipophilicity, rapid and uniform biodistribution, high stability in humans, and ability to provide reliable detection of tumor hypoxia[1][3][5].

Other names: 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide

Beyond the preview

Go deeper on ef5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ef5.

Explore the full profile